头孢他啶-他唑巴坦钠的体内抗菌作用研究

Antibacterial activities of ceftazidime and tazobactam sodium in vivo

目的 探讨头孢他啶-他唑巴坦钠(2:1)对小鼠的体内抗菌活性。方法 采用临床近两年分离的细菌感染小鼠,感染即刻和6 h给予药物治疗,按Bliss法计算ED50值。结果 注射用头孢他啶-他唑巴坦钠(2:1)对产酶的金黄色葡萄球菌和大肠埃希菌感染的小鼠ED50分别为181.9 mg·kg-1和3.4 mg·kg-1,头孢曲松钠-舒巴坦钠(2:1)的ED50值为155.0 mg·kg-1和4.7 mg·kg-1,单组分头孢他啶的ED50值分别为553.6 mg·kg-1和42.7 mg·kg-1,复合制剂(2:1)对铜绿假单胞菌感染小鼠的体内抗菌活性ED50为4.1 mg·kg-1。结论 注射用头孢他啶-他唑巴坦钠对产酶的金黄色葡萄球菌,大肠埃希菌和铜绿假单胞菌感染小鼠有明显的保护作用,抗菌效果明显优于头孢他啶单组分与头孢曲松钠-舒巴坦钠。

OBJECTIVE To explore the antibacterial activities (ED50 value) of the compound of ceftazidime and tazobactam sodium (2 : 1) on disease germs of infected mice in vivo. METHODS Mice infected by the isolated bacteria in clinic in recent two years were subcutaneously injected by some antibiotics including ceftazidime and tazobactam sodium at the instant of infection and 6 h after infection. The values of ED50 were calculated by Bliss method. RESULTS The ED50 values of ceftazidime and tazobactam sodium injection (2:1) that treated mice infected by zymogen-ic staphylococcus aureus and Escherichia coli were 181. 9 mg · kg-1 and 3. 4 mg · kg-1 respectively, those of ceftriax-one sodium and sulbactam sodium injection (2 :1) were 155. 0 mg · kg-1 and 4. 7 mg · kg-1 respectively, and those of single component ceftazidime were 553. 6 mg · kg-1 and 42. 7 mg · kg-1 respectively. The antibacterial activity (ED50 value) of the composite pharmaceutics (2 : 1) that treated mice infected by pseusomonas aeruginosa in vivo was 4. 1 mg · kg-1. CONCLUSIONS Ceftazidime and tazobactam sodium injection can significantly protect mice injected by zymogenic staphylococcus aureus, Escherichia coli and pseudomonas aeruginosa, and its antibacterial effect is better than the single component ceftazidime or ceftriaxone sodium and sulbactam sodium (2 : 1).